• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV-1蛋白酶抑制剂晶体结构的能量计算与分析

Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures.

作者信息

Gustchina A, Sansom C, Prevost M, Richelle J, Wodak S Y, Wlodawer A, Weber I T

机构信息

Macromolecular Structure Laboratory, NCI-Frederick Cancer Research and Development Center, MD 21702.

出版信息

Protein Eng. 1994 Mar;7(3):309-17. doi: 10.1093/protein/7.3.309.

DOI:10.1093/protein/7.3.309
PMID:8177879
Abstract

The interactions between HIV-1 protease and its bound inhibitors have been investigated by molecular mechanics calculations and by analysis of crystal structures of the complexes in order to determine general rules for inhibitor and substrate binding to the protease. Fifteen crystal structures of HIV-1 protease with different peptidomimetic inhibitors showed conservation of hydrogen bond interactions between the main chain C = O and NH groups of the inhibitors and the C = O and NH groups of the protease extending from P3 C = O to P3' NH. The mean length of the hydrogen bonds between the inhibitor and the flexible flaps and the conserved water molecule (2.9 A) is slightly shorter than the mean length of hydrogen bonds between the inhibitor and the more rigid active site region (3.1 A) of the protease. The two hydrogen bonds between the conserved water and P2 and P1' carbonyl oxygen atoms of the inhibitor are the shortest and are predicted to be important for the tight binding of inhibitors. Molecular mechanics analysis of three crystal structures of HIV-1 protease with different inhibitors with independent calculations using the programs Discover and Brugel gave an estimate of 56-68% for the contribution of all the inhibitor main chain atoms to the total calculated protease-inhibitor interaction energy. The contribution of individual inhibitor residues to the interaction energy was calculated using Brugel. The main chain atoms of residue P2 had a consistently large favorable contribution to the total interaction energy, probably due to the presence of the two short hydrogen bonds to the flexible flap.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

为了确定抑制剂和底物与蛋白酶结合的一般规则,已通过分子力学计算以及对复合物晶体结构的分析来研究HIV-1蛋白酶与其结合的抑制剂之间的相互作用。15种含有不同拟肽类抑制剂的HIV-1蛋白酶晶体结构显示,抑制剂的主链C=O和NH基团与蛋白酶从P3 C=O延伸至P3' NH的C=O和NH基团之间存在氢键相互作用。抑制剂与柔性侧翼以及保守水分子之间氢键的平均长度(2.9埃)略短于抑制剂与蛋白酶更刚性的活性位点区域之间氢键的平均长度(3.1埃)。保守水分子与抑制剂的P2和P1'羰基氧原子之间的两个氢键最短,预计对抑制剂的紧密结合很重要。使用Discover和Brugel程序进行独立计算,对三种含有不同抑制剂的HIV-1蛋白酶晶体结构进行分子力学分析,结果表明所有抑制剂主链原子对计算出的蛋白酶-抑制剂总相互作用能的贡献估计为56%-68%。使用Brugel计算单个抑制剂残基对相互作用能的贡献。P2残基的主链原子对总相互作用能始终有很大的正向贡献,这可能是由于与柔性侧翼存在两个短氢键。(摘要截短于250词)

相似文献

1
Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures.HIV-1蛋白酶抑制剂晶体结构的能量计算与分析
Protein Eng. 1994 Mar;7(3):309-17. doi: 10.1093/protein/7.3.309.
2
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.来自与底物类似物结合的HIV-1蛋白酶突变体1.1至1.6埃分辨率晶体结构的底物识别和耐药性的分子基础。
FEBS J. 2005 Oct;272(20):5265-77. doi: 10.1111/j.1742-4658.2005.04923.x.
3
Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.HIV-1蛋白酶与含二羟基乙烯抑制剂复合物的晶体结构:与分子模拟的比较
Protein Sci. 1992 Aug;1(8):1061-72. doi: 10.1002/pro.5560010811.
4
A preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor design.基于偏好的酶-抑制剂结合自由能参数化。在HIV-1蛋白酶抑制剂设计中的应用。
Protein Sci. 1995 Sep;4(9):1881-903. doi: 10.1002/pro.5560040923.
5
Free energy perturbation studies on binding of A-74704 and its diester analog to HIV-1 protease.关于A-74704及其二酯类似物与HIV-1蛋白酶结合的自由能扰动研究。
Protein Eng. 1996 Sep;9(9):767-71. doi: 10.1093/protein/9.9.767.
6
Calculation of relative differences in the binding free energies of HIV1 protease inhibitors: a thermodynamic cycle perturbation approach.
J Med Chem. 1994 Apr 15;37(8):1145-52. doi: 10.1021/jm00034a012.
7
Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors.对称和不对称HIV-1蛋白酶抑制剂中P1 - P3基团的优化
Eur J Biochem. 2003 Apr;270(8):1746-58. doi: 10.1046/j.1432-1033.2003.03533.x.
8
Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.人类免疫缺陷病毒1型蛋白酶与保守的CA-p2底物类似物的晶体学分析——与底物P2'位置常见谷氨酸残基的相互作用。
Eur J Biochem. 1997 Oct 15;249(2):523-30. doi: 10.1111/j.1432-1033.1997.00523.x.
9
Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.一种环磺酰胺HIV-1蛋白酶抑制剂的意外结合模式。
J Med Chem. 1997 Mar 14;40(6):898-902. doi: 10.1021/jm960588d.
10
X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease.一系列源自青霉素的HIV-1蛋白酶不对称抑制剂的X射线晶体学研究。
Biochemistry. 1994 Jul 19;33(28):8417-27. doi: 10.1021/bi00194a005.

引用本文的文献

1
Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance.超越达芦那韦:新一代 HIV-1 蛋白酶抑制剂抵抗耐药性的最新进展。
Chem Commun (Camb). 2022 Oct 20;58(84):11762-11782. doi: 10.1039/d2cc04541a.
2
Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition.结构洞察人类免疫缺陷病毒 (HIV-1) 靶点及其抑制。
Adv Exp Med Biol. 2021;1322:63-95. doi: 10.1007/978-981-16-0267-2_3.
3
Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
涉及P1'-P2'配体的新型大环HIV-1蛋白酶抑制剂的设计、合成、X射线研究及生物学评价
Bioorg Med Chem Lett. 2017 Nov 1;27(21):4925-4931. doi: 10.1016/j.bmcl.2017.09.003. Epub 2017 Sep 6.
4
Design of new potent HTLV-1 protease inhibitors: in silico study.新型强效人嗜T淋巴细胞病毒1型蛋白酶抑制剂的设计:计算机模拟研究
Mol Biol Res Commun. 2016 Mar;5(1):19-30.
5
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.用于治疗艾滋病毒/艾滋病的HIV-1蛋白酶抑制剂开发的最新进展
J Med Chem. 2016 Jun 9;59(11):5172-208. doi: 10.1021/acs.jmedchem.5b01697. Epub 2016 Jan 22.
6
Elucidation of the structure of retroviral proteases: a reminiscence.逆转录病毒蛋白酶结构的阐明:一段回忆
FEBS J. 2015 Nov;282(21):4059-66. doi: 10.1111/febs.13397. Epub 2015 Aug 28.
7
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.增强蛋白主链结合——一种有前途的对抗耐药性 HIV 的概念。
Angew Chem Int Ed Engl. 2012 Feb 20;51(8):1778-802. doi: 10.1002/anie.201102762. Epub 2012 Jan 31.
8
Rational approaches to improving selectivity in drug design.提高药物设计选择性的合理方法。
J Med Chem. 2012 Feb 23;55(4):1424-44. doi: 10.1021/jm2010332. Epub 2012 Jan 12.
9
HIV-1 Protease: Structural Perspectives on Drug Resistance.HIV-1 蛋白酶:耐药性的结构视角。
Viruses. 2009 Dec;1(3):1110-36. doi: 10.3390/v1031110. Epub 2009 Dec 3.
10
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.C3-取代的六氢环戊呋喃基尿嘧啶类作为 P2-配体的 HIV-1 蛋白酶抑制剂的设计:合成、生物评价及蛋白-配体 X 射线晶体结构。
J Med Chem. 2011 Aug 25;54(16):5890-901. doi: 10.1021/jm200649p. Epub 2011 Jul 29.